Recent News

SITC 2022: Cellular Research May Lead to the Next Generation of Therapies for Myeloma

Should Routine Stem Cell Transplantation Be Discontinued in Newly Diagnosed Patients With Myeloma?

SITC 2022: Antigen-Specific Memory CD8-Positive T Cells Target BCMA to Treat Multiple Myeloma

ASTRO 2022: CNS-Directed Radiotherapy for Patients With Extramedullary Multiple Myeloma

ASTRO 2022: Can Radiotherapy Prevent Progression to Myeloma in Patients With Plasmacytomas?

FDA Brief: Bispecific Antibody Receives Breakthrough Therapy Designation in Resistant Myeloma

SLAMF7 Antigen and Myeloma: Therapeutic Target for Antibody-Based and Cellular Immunotherapy?

Daratumumab-Based Chemoimmunotherapy for Multiple Myeloma: Focus on Advanced Renal Failure

ASTRO 2022: Community-Based Registry Offers Glimpse at Use of Radiotherapy for Myeloma

FDA Brief: Teclistamab-cqyv Granted Accelerated Approval in Resistant Myeloma

CD38-CAR Natural Killer Cells: Potential Immunotherapy Target in Multiple Myeloma?

SOHO 2022: Exploring the Role of Salvage Autologous HCT in Myeloma

Gut Microbiota and Gastrointestinal Toxicity From Proteasome Inhibitors in Myeloma

Early-Phase Research on Sotatercept in Combination Therapy for Resistant Multiple Myeloma

SOHO 2022: Update From CARTITUDE-2 of Ciltacabtagene Autoleucel in Multiple Myeloma

Can a Mutational Signature Predict Outcomes With Carfilzomib-Based Therapy for Myeloma?

ASCO Quality 2022: Underrepresentation of Black Patients in Multiple Myeloma Clinical Trials

BCMA-Targeted CAR T-Cell Therapy for Older Patients With Multiple Myeloma

Are Baseline Ocular Conditions Affected by Belantamab Mafodotin Treatment in Myeloma?

Red Cell Distribution Width: A Prognostic Indicator in Newly Diagnosed Multiple Myeloma?

Novel PANGEA Models May Improve Clinical Prediction of Disease Progression to Myeloma

ODAC on Melphalan Flufenamide in Resistant Myeloma: Risk-Benefit Profile Not Favorable for Approved Indication

T-Cell Engagers and Antitumor Immunity in Multiple Myeloma Therapy

ESMO 2022: Wait Time for Diagnosis of Multiple Myeloma in the United States

ESMO 2022: BCMA-Specific CAR T-Cell Therapy Using a Synthetic Binding Domain in Multiple Myeloma

Patient-Reported Outcomes of Clinical Trial Participation Versus Standard Care for Multiple Myeloma

Infectious Complications Among Newly Diagnosed Patients With Myeloma in Latin America

4-Year Study Results With Novel Immunotherapy for Resistant Multiple Myeloma

Do Clinical Trials Match the Demographic and Geographic Diversity of Populations With Blood Cancers?

Quadruplet Therapy for Newly Diagnosed Multiple Myeloma: De-escalation Approach Under Study

Many Caregivers of Patients With Myeloma Struggle With Mental Health Challenges

A Global Evaluation of Multiple Myeloma: Incidence, Mortality, and Risk Factors

Researchers Find Circular RNA May Modulate the Progression of Multiple Myeloma

Triple-Class–Exposed Patients With Myeloma: Ciltacabtagene Autoleucel Versus Real-World Therapies

Follow-up on Elotuzumab-Based Regimen in High-Risk Multiple Myeloma

Teclistamab Plus Daratumumab Under Study in Resistant Multiple Myeloma

Phase II Trial of Daratumumab-Based Regimen in Multiple Myeloma

Novel CAR T-Cell Therapy for Resistant Myeloma in Early-Phase Study

Carfilzomib Plus Lenalidomide and Dexamethasone After ASCT for Multiple Myeloma

Study Update on Teclistamab in Resistant Multiple Myeloma

BCMA-Targeting CAR T-Cell Product for Relapsed or Refractory Multiple Myeloma

Daratumumab-Based Regimen as Salvage Therapy for Resistant Myeloma

ASCO 2022: Combination Therapy With Umbilical Cord Blood–Derived Natural Killer Cells for Myeloma

Can PET/CT Imaging Predict Survival in Multiple Myeloma Relapse?

ASCO 2022: Phase II MagnetisMM-3 Trial Focuses on Elranatamab in Resistant Myeloma

ASCO 2022: Update From Cohort A of CARTITUDE-2 on Ciltacabtagene Autoleucel in Myeloma

ASCO 2022: Ixazomib Plus Daratumumab in Elderly Frail Patients With Resistant Multiple Myeloma

ASCO 2022: Early-Phase Study of Talquetamab in Resistant Multiple Myeloma

ASCO 2022: Daratumumab-Based Therapy for High-Risk Smoldering Myeloma

ASCO 2022: Update From CARTITUDE-1 on Ciltacabtagene Autoleucel in Refractory Myeloma

ASCO 2022: Induction Triplet Regimen With or Without ASCT and Maintenance Therapy for Myeloma

Neuroepigenetic Changes and Their Influence on Bortezomib-Induced Peripheral Neuropathy